Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Gadolinium chelated polysiloxane based nanoparticle (Primary)
- Indications Brain metastases
- Focus Therapeutic Use
- Acronyms NANORAD2
Most Recent Events
- 13 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Aug 2023 Planned End Date changed from 1 Mar 2023 to 26 Mar 2025.
- 16 Aug 2023 Planned primary completion date changed from 1 Mar 2023 to 26 Jun 2024.